CA3255389A1 - Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer - Google Patents

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer

Info

Publication number
CA3255389A1
CA3255389A1 CA3255389A CA3255389A CA3255389A1 CA 3255389 A1 CA3255389 A1 CA 3255389A1 CA 3255389 A CA3255389 A CA 3255389A CA 3255389 A CA3255389 A CA 3255389A CA 3255389 A1 CA3255389 A1 CA 3255389A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
egfr tki
egfr
capivasertib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3255389A
Other languages
English (en)
French (fr)
Inventor
Nicolas Floch
Matthew Joseph Martin
Paul David SMITH
Ursula GRAZINI
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA3255389A1 publication Critical patent/CA3255389A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3255389A 2022-03-31 2023-03-30 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer Pending CA3255389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263325861P 2022-03-31 2022-03-31
US63/325,861 2022-03-31
PCT/EP2023/058261 WO2023187037A1 (en) 2022-03-31 2023-03-30 Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3255389A1 true CA3255389A1 (en) 2023-10-05

Family

ID=86007676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3255389A Pending CA3255389A1 (en) 2022-03-31 2023-03-30 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer

Country Status (11)

Country Link
US (1) US20250205233A1 (enExample)
EP (1) EP4499102A1 (enExample)
JP (1) JP2025510910A (enExample)
KR (1) KR20240168418A (enExample)
CN (1) CN119278041A (enExample)
AU (1) AU2023246862A1 (enExample)
CA (1) CA3255389A1 (enExample)
IL (1) IL315848A (enExample)
MX (1) MX2024011959A (enExample)
TW (1) TW202408514A (enExample)
WO (1) WO2023187037A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20250538A (es) * 2023-05-26 2026-04-21 Astrazeneca Ab Composiciones farmacéuticas
KR20260024838A (ko) * 2024-08-14 2026-02-23 경희대학교 산학협력단 프로토사파닌 b 및 오시머티닙을 유효성분으로 포함하는 폐암의 예방 또는 치료용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP20110958T1 (hr) 2004-05-06 2012-01-31 Warner-Lambert Company Llc 4-fenilaminokinazolin-6-ilamidi
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
US8481503B2 (en) * 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
SG11201401953WA (en) 2011-10-31 2014-09-26 Betta Pharmaceuticals Co Ltd Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (zh) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (zh) 2015-04-29 2020-03-10 广东众生药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
WO2019126739A1 (en) * 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
WO2023035223A1 (zh) * 2021-09-10 2023-03-16 上海艾力斯医药科技股份有限公司 药物组合物及其用途

Also Published As

Publication number Publication date
JP2025510910A (ja) 2025-04-15
IL315848A (en) 2024-11-01
AU2023246862A1 (en) 2024-10-31
EP4499102A1 (en) 2025-02-05
WO2023187037A1 (en) 2023-10-05
TW202408514A (zh) 2024-03-01
US20250205233A1 (en) 2025-06-26
MX2024011959A (es) 2024-12-06
KR20240168418A (ko) 2024-11-29
CN119278041A (zh) 2025-01-07

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
JP7667132B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20250205233A1 (en) Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
EP3010505A1 (en) Pharmaceutical combinations
WO2016193955A1 (en) Combinations of kinase inhibitors for treating colorectal cancer
US12606616B2 (en) PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US20230056604A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
US20210161897A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
HK40120753A (en) Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023044065A1 (en) Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
US20260137681A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2025179032A1 (en) Methods of treating myelofibrosis

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240924

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250122

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250122

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250217

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250918